Ask about this productRelated genes to: PFDN2 Blocking Peptide
- Gene:
- PFDN2 NIH gene
- Name:
- prefoldin subunit 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-08-06
- Date modifiied:
- 2014-11-19
Related products to: PFDN2 Blocking Peptide
Related articles to: PFDN2 Blocking Peptide
- Head and neck squamous cell carcinoma (HNSC) is a highly heterogeneous malignancy with poor prognosis and frequent recurrence. Beyond tumor-intrinsic alterations, the immune microenvironment plays a decisive role in tumor initiation and progression. However, the causal contribution of systemic plasma proteins to immune regulation and HNSC susceptibility remains poorly defined. - Source: PubMed
Publication date: 2026/03/10
Feng ChenLi CeLei Dapeng - Colorectal cancer (CRC) progression entails coordinated gene dysregulation and rewiring of signaling networks. Here, we investigated whether prefoldin subunit 2 (PFDN2) contributes to CRC progression by stabilizing pyrroline-5-carboxylate reductase 2 (PYCR2) and thereby modulating Wnt/β-catenin signaling. Integrated analyses of TCGA-COAD/READ and other public datasets showed that PFDN2 and PYCR2 are upregulated in CRC, positively correlated, and associated with poorer prognosis. These findings were corroborated in a 30-pair immunohistochemistry (IHC) cohort, and target modulation was confirmed by quantitative real-time PCR and Western blotting. Gain- and loss-of-function studies showed that PFDN2 promotes, whereas its knockdown suppresses, CRC cell proliferation and migration in vitro; in vivo, PFDN2 silencing reduced xenograft growth and Ki-67/β-catenin expression. PYCR2 was likewise elevated in CRC, linked to adverse clinicopathologic features, and enhanced proliferative and migratory phenotypes. Mechanistically, co-immunoprecipitation and immunofluorescence analyses revealed a PFDN2–PYCR2 interaction with predominantly cytoplasmic colocalization. PFDN2 manipulation altered PYCR2 protein but not mRNA levels; cycloheximide chase and MG132 rescue experiments indicated that PFDN2 stabilizes PYCR2 by limiting proteasome-dependent degradation. PFDN2 or PYCR2 depletion reduced TOP/FOPflash reporter activity, nuclear β-catenin accumulation, and expression of canonical Wnt targets, whereas PYCR2 re-expression partially restored these readouts and migratory capacity in PFDN2-silenced cells. Pharmacologic inhibition of canonical Wnt/β-catenin signaling attenuated the pro-proliferative and pro-migratory effects of PFDN2 or PYCR2 overexpression. The PFDN2–PYCR2–Wnt/β-catenin axis appears to be involved in CRC progression, and both proteins may have potential value as prognostic biomarkers and as candidates for further investigation as therapeutic targets. - Source: PubMed
Publication date: 2026/02/09
Chang XinChen PanLi LingCao JinzhongHou ShaohuaLi Hai - Colorectal cancer (CRC) is a prevalent and lethal malignancy that imposes significant burdens on patients and healthcare systems worldwide. This study aimed to explore the significance of ribosome biogenesis (RiboSis)-related genes (RRGs) in CRC and their clinical implications. The scRNA-seq data of three CRC tissues were sourced from the Gene Expression Omnibus (GEO) database. Nonnegative matrix factorization (NMF) was employed to categorize cell subtypes associated with RiboSis. An integrative machine learning approach encompassing ten algorithms was subsequently implemented to develop a prognostic signature. Our research revealed 295 differentially expressed RiboSis-related genes (DERRGs) associated with survival outcomes, with a notable RiboSis score that was markedly higher in CRC tissues than in normal counterparts. Univariate Cox analysis revealed 25 DERRGs with significant survival differences (P < 0.05). scRNA-seq of 26,961 cells from 13 CRC samples revealed eight major cell types, with T and B cells predominantly enriched in immune response pathways. InferCNV analysis distinguished malignant epithelial cells on the basis of copy number variations, and NMF identified four RiboSis-related cell subtypes. Our RiboSis-related prognostic model, validated across the TCGA, GSE17536, and GSE39582 datasets, demonstrated high predictive accuracy. Notably, low RiboSis signature scores were correlated with reduced immune evasion risk and upregulated immune checkpoint genes, suggesting enhanced responsiveness to immunotherapy. Among the 8 model genes, PFDN2 was considered the hub gene. The experimental results of PFDN2 in this RiboSis signature indicated that PFDN2 expression is elevated in CRC tissues and that PFDN2 knockdown promotes the proliferation, migration, and invasion of CRC cells. This study underscores the potential of RRGs as biomarkers and therapeutic targets, offering new avenues for personalized CRC management. - Source: PubMed
Publication date: 2025/08/21
Song WeiZhou MinWang YataoGuo FengqinLiu Yanliang - Quantitative real-time PCR (qRT-PCR) has been widely employed for the study of gene expression in fish, and accurate normalization is crucial. In this study, we aimed to identify the most stably expressed genes in various tissues, different developmental stages, and within astaxanthin treatment groups in Lutjanus erythropterus. Twelve candidate genes (EEF1A, CYB5R3, DLD, IDH3A, MRPL17, MRPL43, NDUFS7, PABPC1, PAGR1, PFDN2, PSMC3, and RAB10) were examined via qRT-PCR. We employed geNorm and NormFinder to assess their stability. The results revealed that RAB10 and PFDN2 exhibited relatively stable expression patterns across different tissue and astaxanthin treatment groups, while NDUFS7 and MRPL17 proved to be the most reliable reference gene combinations across various developmental stages. The stability of these selected genes was further validated by assessing the expression of two target genes, CRADD and CAPNS1, across developmental stages, reinforcing the reliability of NDUFS7 as it closely aligned with transcriptome-wide expression patterns at these stages. The present results will help researchers to obtain more accurate results in future qRT-PCR analysis in L. erythropterus. - Source: PubMed
Publication date: 2024/06/10
Chen LujunLiang QiuluLai ZhuoxinCui HaitaoXu ZhenminChen ZizhaoDong ZhongdianWang ZhongduoGuo Yusong - Gastric cancer (GC) is a major health burden worldwide, but our understanding of GC is limited, and the prognosis is poor. Novel therapeutic strategies and biomarkers are urgently needed to improve GC patient outcomes. Previously, we identified PFDN2 as a novel key gene in gastric cancer based on its differential expression between cancer and normal tissues. However, the role and underlying mechanisms of PFDN2 in GC remain elusive. In this article, we demonstrated that PFDN2 is highly expressed in GC and that upregulation of PFDN2 is associated with the progression of GC. We further found that PFDN2 could promote cell cycle progression by promoting MYBL2 expression. Mechanistically, we demonstrated that PFDN2 could upregulate MYBL2 expression by facilitating the nuclear translocation of hnRNPD, and thus promoting MYBL2 transcriptional program. In conclusion, we found that PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis and may serve as a potential biomarker and therapeutic target for GC. - Source: PubMed
Publication date: 2023/07/18
He QiumingDing ZheyuChen TingnaWu HaitaoSong JialingXiang ZhenxianYang ChaogangWang ShuyiXiong Bin